PCUR-101 / Pellficure - LARVOL DELTA

Study of PCUR-101 in Combination With ADT in Patients With mCRPC (clinicaltrials.gov) - P1 | N=7 | Terminated | Sponsor: Pellficure Pharmaceuticals, Inc | N=48 ➔ 7 | Recruiting ➔ Terminated; Business Decision due to insufficient enrollment

Combination therapy • Enrollment change • Metastases • Trial termination • Genito-urinary Cancer • Metastatic Castration-Resistant Prostate Cancer • Oncology • Prostate Cancer • Solid Tumor

A phase I dose escalation study of PCUR-101 in men with metastatic castration-resistant prostate cancer (mCRPC). (ASCO 2019) - P1; "At the doses evaluated, PCUR-101 combined with ADT was seen to be safe and may prolong disease stability in men with mCRPC. A second phase I study is planned using a new drug formulation and PK assay. Clinical trial information: NCT03137758"

P1 data

Study of PCUR-101 in Combination With ADT in Patients With mCRPC (clinicaltrials.gov) - P1 | N=48 | Recruiting | Sponsor: Pellficure Pharmaceuticals, Inc | Trial completion date: Jun 2023 ➔ Dec 2023 | Trial primary completion date: Jun 2023 ➔ Dec 2023

Trial completion date • Trial primary completion date • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor

Study of PCUR-101 in Combination With ADT in Patients With mCRPC (clinicaltrials.gov) - P1; N=48; Recruiting; Sponsor: Pellficure Pharmaceuticals, Inc; Not yet recruiting ➔ Recruiting; Initiation date: Jan 2021 ➔ Apr 2021

Clinical • Combination therapy • Enrollment open • Trial initiation date • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor

Study of PCUR-101 in Combination With ADT in Patients With mCRPC (clinicaltrials.gov) - P1; N=48; Not yet recruiting; Sponsor: Pellficure Pharmaceuticals, Inc

Clinical • Combination therapy • New P1 trial • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor

A Phase I Study of PCUR-101 in Combination With Androgen Suppression Therapy in the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer (clinicaltrials.gov) - P1; N=12; Terminated; Sponsor: Pellficure Pharmaceuticals, Inc; Active, not recruiting ➔ Terminated; Reformulation of study drug to help reduce the pill burden as higher doses are evaluated.

Clinical • Combination therapy • Trial termination

A Phase I Study of PCUR-101 in Combination With Androgen Suppression Therapy in the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer (clinicaltrials.gov) - P1; N=12; Active, not recruiting; Sponsor: Pellficure Pharmaceuticals, Inc; Recruiting ➔ Active, not recruiting; N=48 ➔ 12

Clinical • Combination therapy • Enrollment change • Enrollment closed